Boston, MA -- (SBWIRE) -- 09/06/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Array Biopharma Inc (NASDAQ:ARRY), InvenSense Inc (NYSE:INVN), Cypress Semiconductor Corporation (NASDAQ:CY), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Array Biopharma Inc (NASDAQ:ARRY) shares dropped 3.56% to $5.69. The company announced that its Chief Executive Officer, Ron Squarer, will present at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 10, 2013 at 12:20 p.m. ET.
Additionally, the company on August 7 said it would cut 20 percent of its workforce as Amgen Inc plans to end an agreement to develop and market Array's drug to treat Type 2 diabetes. The company said it would record a one-time restructuring charge of $2.7 million in the first quarter of fiscal 2014. The company said it would have 200 employees after cutting 50 jobs. Most of the job cuts will be in the company's drug discovery business.
How Should Investors Trade ARRY After The Recent Volatility? Get Free Report Here
InvenSense Inc (NYSE:INVN) shares increased 1.28% to $18.23. The company on Sept. 4 announced the appointment of Mr. Eric Stang to its Board of Directors. The election of Mr. Stang increases the size of InvenSense's board to seven members. Mr. Stang currently serves as a Director and President and Chief Executive Officer of Ooma, Inc., a provider of broadband telephony products, a position he has held since January 2009.
Additionally, Investment analysts at Needham & Company began coverage on shares of INVN in a note issued to investors on August 22. The firm set a “buy” rating and a $20.00 price target on the stock.
How Should Investors Trade INVN After The Recent Volatility? Get Free Report Here
Cypress Semiconductor Corporation (NASDAQ:CY) stock increased 1.79% to $11.40. The company on August 29 announced that Executive Vice President of Finance and Chief Financial Officer, Brad Buss, will discuss Cypress's business and strategic outlook at two investor events in September. First, Buss will present at the 2013 Citi Technology Conference on September 4 at the Hilton Hotel in New York. The presentation will begin at 11:15 a.m. Eastern Time. Second, Buss will address the Deutsche Bank 2013 dbAccess Technology Conference at The Cosmopolitan of Las Vegas on September 10 at 11:00 a.m. Pacific Time.
Is CY A Good Buy After The Recent Price Movement? Find Out Here
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares climbed 5.41% to $7.02. The company on August 7 reported financial results for the three and six months ended June 30, 2013 and provided an update on the Company's portfolio of clinical stage compounds being developed for the treatment of the hepatitis C virus (HCV).
For the second quarter of 2013, Achillion reported a net loss of $19.9 million or $0.21 per share, compared with a net loss of $11.5 million or $0.16 per share for the second quarter of 2012. Cash, cash equivalents, marketable securities, and interest receivable as of June 30, 2013 were $187.4 million.
Is ACHN A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)